New therapeutic targets for the treatment of high-risk neuroblastoma

Journal of Cellular Biochemistry

Volumn 107, Issue 1, 2009, Pages 46-57

  Wagner, Lars M ^a   Danks, Mary K ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Neuroblastoma; Novel therapeutic targets

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ANTINEOPLASTIC AGENT; BETA GLUCAN; BEVACIZUMAB; BORTEZOMIB; BUTHIONINE SULFOXIMINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; EFLORNITHINE; ETOPOSIDE; FENRETINIDE; IMC A12; IRINOTECAN; ISOTRETINOIN; LESTAURTINIB; MELPHALAN; MLN 8237; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NIFURTIMOX; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; TEMSIROLIMUS; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VINBLASTINE; VINCRISTINE; VORINOSTAT; YTTRIUM 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE] Y 90; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CHILD; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; NEUROBLASTOMA; RADIOTHERAPY;

EID: 66149171647     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22094     Document Type: Article

References (109)

1. Aboody KS, Bush RA, Garcia E, Metz M, Najbauer J, Justus KA, Phelps DA, Remack JS, Yoon KJ, Gillespie S, Kim SU, Glackin C, Potter PM, Danks MK. 2006. Neural progenitor cells expressing a therapeutic transgene target metastatic neuroblastoma and mediate long-term survival in a mouse model. PLoS ONE 1(1):e23. DOI: 10.1371/journal.pone.0000023.
2. Anderson CP, Seeger RC, Satake N, Monforte-Munoz HL, Keshelava N, Bailey HH, Reynolds CP. 2001. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J Pediatr Hematol Oncol 23:500-505.
3. Armstrong MB, Schumacher KR, Mody R, Yanik GA, Opipari AW, Jr., Castle VP. 2008. Bortezomib as a therapeutic candidate for neuroblastoma. J Exp Ther Oncol 7:135-145.
4. Barker SE, Grosse SM, Siapati EK, Kritz A, Kinnon C, Thrasher AJ, Hart SL. 2007. Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12. Br J Cancer 97:210-217.
5. Beiske K, Ambros PF, Burchill SA, Cheung IY, Swerts K. 2005. Detecting minimal residual disease in neuroblastoma patients - The present state of the art. Cancer Lett 228:229-240.
6. Bolesta E, Kowalczyk A, Wierzbicki A, Rotkiewicz P, Bambach B, Tsao CY, Horwacik I, Kolinski A, Rokita H, Brecher M, Wang X, Ferrone S, Kozbor D. 2005. DNA vaccine expressing the mimotope of GD2 gangliside induces protective GD2 cross-reactive antibody responses. Cancer Res 65:3410-3418.
7. Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias MV, Pistoia V, Ribatti D, Pagnan G, Ponzoni M. 2006. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 98:1142-1157.
8. Burchill SA, Lewis IJ, Abrams KR, Riley R, Imeson J, Pearson AD, Pinkerton R, Selby P. 2001. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 19:1795-1801.
9. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D, Weiss WA. 2006. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 66:8139-8146. Erratum in: Cancer Res. 66:10227.
10. Cheung NK, Modak S. 2002. Oral (1->3),(1->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res 8:1217-1223.
11. Cheung NK, Kushner BH, LaQuaglia M, Kramer K, Gollamudi S, Heller G, Gerald W, Yeh S, Finn R, Larson SM, Wuest D, Byrnes M, Dantis E, Mora J, Cheung IY, Rosenfield N, Abramson S, O'Reilly RJ. 2001. N7: A novel multimodality therapy of high ris: Neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol 36:227-230.
12. Cheung IY, Lo Piccolo MS, Kushner BH, Kramer K, Cheung NK. 2003. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: Clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol 21:1087-10893.
13. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL. 2008. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8.
14. Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R, Puisieux A. 2008. Effect of bortezomib on human neuroblastoma: Analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer 7:50.
15. Cotterman R, Jin VX, Krig SR, Lemen JM, Wey A, Farnham PJ, Knoepfler PS. 2008. N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res 68:9654-9662.
16. Coughlin CM, Fleming MD, Carroll RG, Pawel BR, Hogarty MD, Shan X, Vance BA, Cohen JN, Jairaj S, Lord EM, Wexler MH, Danet-Desnoyers GA, Pinkus JL, Pinkus GS, Maris JM, Grupp SA, Vonderheide RH. 2006. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. J Clin Oncol 24:5724-5734.
17. Coulter DW, Blatt J, D'Ercole AJ, Moats-Staats BM. 2008. IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth. Anticancer Res 28:1509-1516.
18. Croce M, Meazza R, Orengo AM, Fabbi M, Borghi M, Ribatti D, Nico B, Carlini B, Pistoia V, Corrias MV, Ferrini S. 2008. Immunotherapy of neuroblastoma by an interleukin-21-secreting cell vaccine involves survivin as antigen. Cancer Immunol Immunother 57:1625-1634.
19. Danks MK, Yoon KJ, Bush RA, Remack JS, Wierdl M, Tsurkan L, Kim SU, Garcia E, Metz MZ, Najbauer J, Potter PM, Aboody KS. 2007. Tumor-targeted enzyme-prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res 67(1): 1-4.
20. de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN. 2008. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 44:551-556.
21. De los Santos M, Zambrano A, Aranda A. 2007. Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. Mol Cancer Ther 6:1425-1432.
22. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM. 2007. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13:3942-3950.
23. DiPaolo D, Pastorino F, Brignole C, Marimpietri D, Loi M, Ponzoni M, Pagnan G. 2008. Drug delivery systems: Application of liposomal anti-tumor agents to neuroectodermal cancer treatment. Tumori 94:246-253.
24. Donev RM, Gray LC, Sivasankar B, Hughes TR, van den Berg CW, Morgan BP. 2008. Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma. Cancer Res 68:5979-5987.
25. DuBois SG, Matthay KK. 2008. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 35:S35-S48.
26. Fest S, Huebener N, Weixler S, Bleeke M, Zeng Y, Strandsby A, Volkmer-Engert R, Landgraf C, Gaedicke G, Riemer AB, Michalsky E, Jaeger IS, Preissner R, Forster-Wald E, Jensen-Jarolim E, Lode HN. 2006. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res 66:10567-10575.
27. Finklestein JZ, Krailo MD, Lenarsky C, Ladisch S, Blair GK, Reynolds CP, Sitarz AL, Hammond GD. 1992. 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: Report from the Childrens Cancer Study Group. Med Pediatr Oncol 20:307-311.
28. Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. 2008. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 52:334-340.
29. Fouladi M, Park JR, Sun J, Ingle AM, Ames MM, Stewart CF, Gilbertson R, Zwiebel JA, Adamson PC, Blaney SM. 2008. A phase I trial and pharmacokinetic (PK) study of vorinostat (SAHA) in combination with 13 cis-retinoic acid (13cRA) in children with refractory neuroblastomas, medulloblastomas, primitive neuroectodermal tumors (PNETs), and atypical teratoid rhabdoid tumor. J Clin Oncol 26: abstr 10012.
30. Fox E, Maris JM, Widemann BC, Goodspeed W, Goodwin A, Kromplewski M, Fouts ME, Medina D, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM. 2008. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 14:1111-1115.
31. Frantz CN, London WB, Diller L, Seeger R, Sawyer K; Dupont Hospital, Wilmingon, DE; COG Statistics Dept, Gainesville, FL; Dana-Farber Cancer Institute, Boston, MA; Children's Hospital Los Angeles, Los Angeles, CA; University of Maryland, Baltimore, MD. 2004. Recurrent neuroblastoma: Randomized treatment with topotecan + cyclophosphamide (T + C) vx. topotecan alone(T). A POG/CCG Intergroup Study. J Clin Oncol 22: abstr 8512.
32. Fukuda M, Miyajima Y, Miyashita Y, Horibe K. 2001. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: A pilot study. J Pediatr Hematol Oncol 23:10-13. (Pubitemid 32124978)
33. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Jr., Gandara DR. 2008. Aurora kinases as anticancer drug targets. Clin Cancer Res 14:1639-1648.
34. George RE, Sanda T, Hanna M, Frohling S, Luther W, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT. 2008. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455:975-978.
35. Gilman AL, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, Sternberg A, Hank JA, Seeger R, Reaman GH, Sondel PM. 2009. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: A report from the Children's Oncology Group. J Clin Oncol 27:85-91.
36. Hamner JB, Dickson PV, Sims TL, Zhou J, Spence Y, Ng CY, Davidoff AM. 2007. Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma. Surgery 142:185-191.
37. Himoudi N, Yan M, Papanastasiou A, Anderson J. 2008. MYCN as a target for cancer immunotherapy. Cancer Immunol Immunother 27:693-700.
38. Hogarty MD, Norris MD, David K, Liu X, Evageliou NF, Hayes CS, Pawel B, Guo R, Zhao H, Sekyere E, Keating J, Thomas W, Cheng NC, Murray J, Smith J, Sutton R, Venn N, London WB, Tuxton A, Gilmour SK, Marshall GM, Haber M. 2008. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 58:9735-9745.
39. Houghton PJ, Morton CL, Maris JM, Courtright J, Carol H, Lock RB, Friedman HS, Keir ST, Gorlick R, Kolb EA, Reynolds CP, Kang M, Smith M. 2008. Pediatric Preclinical Testing Program (PPTP) evaluation of the Aurora A Kinase inhibitor MLN 8237. Proceedings of the 99th American Association for Cancer Research Annual Meeting April 12-16, 2008. San Diego, CA, abstr 2997.
40. Huebener N, Fest S, Strandsby A, Michalsky E, Preissner R, Zeng Y, Gaedicke G, Lode HN. 2008. A rationally designed tyrosine hydroxylase DAN vaccine induces specific antineuroblastoma immunity. Mol Cancer Ther 7:2241-2251.
41. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. 2002. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 16:771-780.
42. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342.
43. Johnsen JI, Segerström L, Orrego A, Elfman L, Henriksson M, Kågedal B, Eksborg S, Sveinbjörnsson B, Kogner P. 2008. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 27:2910-2922.
44. Kieran MW, Turner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, Klement G, Laforme A, Gordon A, Thomas A, Neuberg D, Browder T, Folkman J. 2005. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 27:573-581.
45. Kohler JA, Imeson J, Ellershaw C, Lie SO. 2000. A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy. Br J Cancer 83:1124-1127.
46. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. 2008. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 50:1190-1197.
47. Kreissman SG, Villablanca JG, Diller L, London WB, Maris JM, Park JR, Reynolds CP, von Allmen D, Cohn SL, Matthay KK. 2007. Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG A3973) study. J Clin Oncol 24: abstr 9505.
48. Kushner BH, Cheung NK. 1989. GM-CSF enhances 3F8 monoclonal antibody- dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73:1936-1941.
49. Kushner BH, Kramer K, Modak S, Cheung NK. 2006. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 24:5271-5276.
50. Kushner BH, Cheung IY, Kramer K, Modak S, Cheung NK. 2007. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: Broad implications for immunotherapy. Pediatr Blood Cancer 48:430-4304.
51. Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D. 2004. Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol 26:227-232.
52. Laverdière C, Cheung NK, Kushner BH, Kramer K, Modak S, LaQuaglia MP, Wolden S, Ness KK, Gurney JG, Sklar CA. 2005. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 45:324-332.
53. Lipton A. 2008. Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 34:S25-S30.
54. Liu X, Turbyville T, Fritz A, Whitesell L. 1998. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res 58:5432-5438.
55. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA. 1998. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91:1706-1715.
56. Lovat PE, Corazzari M, Goranov B, Piacentini M, Redfern CP. 2004. Molecular mechanisms of fenretinide-induced apoptosis of neuroblastoma cells. Ann NY Acad Sci 1028:81-89.
57. Ma Z, Cools J, Marynen P, Cui X, Siebert R, Gesk S, Schlegelberger B, Peeters B, De Wolf-Peeters C, Wlodarska I, Morris SW. 2000. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 95:2144-2149.
58. Mahller YY, Vaikunth SS, Ripberger MC, Baird WH, Saeki Y, Cancelas JA, Crombleholme TM, Cripe TP. 2008. Tissue inhibitor of metalloproteinase-3 via oncolytic Herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res 68:1170-1179.
59. Marimpietri D, Brignole C, Nico B, Pastorino F, Pezzolo A, Piccardi F, Cilli M, Di Paolo D, Pagnan G, Longo L, Perri P, Ribatti D, Ponzoni M. 2007. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin Cancer Res 13:3977-3988.
60. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. 1999. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341:1165-1173.
61. Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM, Valteau-Couanet D, Hartmann O, Michon J. 2003. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 21:2486-2491.
62. Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. 2006. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 24:500-506.
63. Maurer BJ, Kalous O, Yesair DW, Wu X, Janeba J, Maldonado V, Khankaldyyan V, Frgala T, Sun BC, McKee RT, Burgess SW, Shaw WA, Reynolds CP. 2007. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex. Clin Cancer Res 13:3079-3086.
64. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L, Ulkus LE, Kuhlmann G, Greninger P, Christensen JG, Haber DA, Settleman J. 2008. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 68:3389-3395.
65. McKenzie PP, Guichard SM, Middlemas DS, Ashmun RA, Danks MK, Harris LC. 1999. Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated. Clin Cancer Res 5:4199-4207.
66. Modak S, Cheung NK. 2007. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 25:67-77.
67. Morton CL, Favours EG, Mercer KS, Boltz CR, Crumpton JC, Tucker C, Billups CA, Houghton PJ. 2007. Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs 25:285-295.
68. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM. 2008. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455:930-935.
69. Natale RB. 2008. Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. J Thorac Oncol 3:S128-S130.
70. Opel D, Poremba C, Simon T, Debatin KM, Fulda S. 2007. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 67:735-745.
71. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508. (Pubitemid 43259931)
72. Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, Matthay KK, Reaman GH, Seeger RC. 2000. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: A Children's Cancer Group Study. J Clin Oncol 18:4077-4085.
73. Park JR, Stewart CF, London WB, Santana VM, Shaw PJ, Cohn SL, Matthay KK. 2006. A topotecan-containing induction regimen for treatment of high-risk neuroblastoma. J Clin Oncol 24:abstr 9013.
74. Park JR, Eggert A, Caron H. 2008. Neuroblastoma: Biology, prognosis, and treatment. Pediatr Clin North Am 55:97-120.
75. Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D, Pagnan G, Piccardi F, Cilli M, Longhi R, Ribatti D, Corti A, Allen TM, Ponzoni M. 2006. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 66:10073-10082.
76. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D, European Neuroblastoma Study Group, Children's Cancer and Leukaemia Group (CCLG formerly United Kingdom Children's Cancer Study Group). 2008. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial. Lancet Oncol 9:247-256.
77. Peng H, Sohara Y, Moats RA, Nelson MD, Jr., Groshen SG, Ye W, Reynolds CP, DeClerck YA. 2007. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Res 67:9346-9355.
78. Pezzolo A, Parodi F, Corrias MV, Cinti R, Gambini C, Pistoia V. 2007. Tumor origin of endothelial cells in human neuroblastoma. J Clin Oncol 25:376-383.
79. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. 2008. Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14:1264-1270.
80. Qiao J, Kang J, Ishola TA, Rychahou PG, Evers BM, Chung DH. 2008. Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma. Proc Natl Acad Sci 105:12891-12896.
81. Radhakrishnan SK, Halasi M, Bhat UG, Kurmasheva RT, Houghton PJ, Gartel AL. 2008. Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells. Oncogene 27:694-699.
82. Rosati SF, Williams RF, Nunnally LC, McGee MC, Sims TL, Tracey L, Zhou J, Fan M, Ng CY, Nathwani AC, Stewart CF, Pfeffer LM, Davidoff AM. 2008. IFN-b sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression. Mol Cancer Ther 7:3852-3858.
83. Rössler J, Taylor M, Geoerger B, Farace F, Lagodny J, Peschka-Süss R, Niemeyer CM, Vassal G. 2008. Angiogenesis as a target in neuroblastoma. Eur J Cancer 44:1645-1656.
84. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. 2007. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13(18 Pt 2):5549s-5555s.
85. Rubie H, Chisholm J, Defachelles AS, Morland B, Munzer C, Valteau-Couanet D, Mosseri V, Bergeron C, Weston C, Coze C, Auvrignon A, Djafari L, Hobson R, Baunin C, Dickinson F, Brisse H, McHugh K, Biassoni L, Giammarile F, Vassal G, Société Françaisedes Cancers de l'Enfant, United Kingdom Children Cancer Study Group-New Agents Group Study. 2006. Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: A joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study. J Clin Oncol 24:5259-5264.
86. Sartelet H, Oligny LL, Vassal G. 2008. AKT pathway in neuroblastoma and its therapeutic implication. Expert Rev Anticancer Ther 8:757-769.
87. Saulnier Sholler GL, Kalkunte S, Greenlaw C, McCarten K, Forman E. 2006. Antitumor activity of nifurtimox observed in a patient with neuroblastoma. J Pediatr Hematol Oncol 28:693-695.
88. Schramm A, Schulte JH, Astrahantseff K, Apostolov O, Limpt V, Sieverts H, Kuhfittig-Kulle S, Pfeiffer P, Versteeg R, Eggert A. 2005. Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Lett 228:143-153.
89. Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, Krause M, Astrhantseff K, Klein-Hitpass L, Buettner R, Schramm A, Christiansen H, Eilers M, Eggert A, Berwanger B. 2008. MYCN regulates oncogenic micro-RNAs in neuroblastoma. Int J Cancer 122:699-704.
90. Shusterman S, London WB, Gillies SD, Hank JA, Voss S, Seeger RC, Hecht T, Reisfeld RA, Maris JM, Sondel PM. 2008. Anti-neuroblastoma activity of hu14.18-lL2 against minimal residual disease in a Children's Oncology Group (COG) phase II study. J Clin Oncol 26:asbstr 3002.
91. Sims TL, Hamner JB, Bush RA, Williams RF, Zhou J, Kim SU, Aboody KS, Danks MK, Davidoff AM. 2008. Neural progenitor cell-mediated delivery of interferon beta improves neuroblastoma response to cyclophosphamide. Ann Surg Oncol 15:3259-3267.
92. Singleton JR, Randolph AE, Feldman EL. 1996. Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. Cancer Res 56:4522-4529.
93. Song L, Ara T, Wu HW, Woo CW, Reynolds CP, Seeger RC, DeClerck YA, Thiele CJ, Sposto R, Metelitsa LS. 2007. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J Clin Invest 117:2702-2712.
94. Spunt SL, Grupp S, Vik T, Santana VM, Greenblatt DJ, Gilbertson R, Hewes B, Boni J, Esteves B, Speicher L. 2008. Phase I safety, pharmacokinetic and exploratory biomarker study of intravenous temsirolimus in children with advanced solid tumors. Proc Am Soc Ped Hem/Onc, Cincinnati, OH.
95. Stempak D, Gammon J, Halton J, Moghrabi A, Koren G, Baruchel S. 2006. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 28:720-728.
96. Tanaka N, Fukuzawa M. 2008. MYCN downregulates integrin alpha1 to promote invasion of human neuroblastoma cells. Int J Oncol 33:815-821.
97. Tang XX, Zhao H, Kung B, Kim DY, Hicks SL, Cohn SL, Cheung NK, Seeger RC, Evans AE, Ikegaki N. 2006. The MYCN enigma: Significance of MYCN expression in neuroblastoma. Cancer Res 66:2826-2833.
98. Tong HX, Lu CS, Zhang JH, Zhang JH. 2008. Enhanced effect of IFNgamma on the induced apoptosis of neuroblastoma cells by cytotoxic drugs. Pediatr Hematol Oncol 25:549-558.
99. Valentiner U, Valentiner FU, Schumacher U. 2008. Expression of CD44 is associated with a metastatic pattern of human neuroblastoma cells in a SCID mouse xenograft model. Tumour Biol 29:152-160.
100. van Maerken T, Speleman F, Vermeulen J, Lambertz I, DeClercq S, DeSmet E, Yigit N, Coppens V, Phillippe J, DePaepe A, Marine JC, Vandesompele J. 2006. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 66:9646-9655.
101. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP. 2006. Phase I trial of oral fenretinide in children with high-risk solid tumors: A report from the Children's Oncology Group (CCG 09709). J Clin Oncol 24:3423-3430. Erratum in: J Clin Oncol 24:4223.
102. Vredenburgh JJ, Desjardins A, Herndon JE II, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. 2007. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259.
103. Wagner LM, McLendon RE, Yoon KJ, Weiss BD, Billups CA, Danks MK. 2007. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. Clin Cancer Res 13:5418-5425.
104. Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KK. 2009. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium study. J Clin Oncol [Epub ahead print].
105. Wu W, Luo Y, Sun C, Liu Y, Kuo P, Varga J, Xiang R, Reisfeld R, Janda KD, Edgington TS, Liu C. 2006. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res 66:970-980.
106. Yan X, Johnson BD, Orentas RJ. 2008. Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L. J Immunol 181:4621-4631.
107. Yoon KJ, Phelps DA, Bush RA, Remack JS, Billups CA, Khoury JD. 2008. Intercellular adhesion molecule-2 mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma. PLoS ONE 3(11):e3629. DOI: 10.1371/journal.pone.0003629.
108. Zage PE, Kletzel M, Murray K, Marcus R, Castleberry R, Zhang Y, London WB, Kretschmar C, Children's Oncology Group. 2008. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 51:747-753.
109. Zeng Y, Huebener N, Fest S, Weixler S, Schroeder U, Gaedicke G, Xiang R, Schramm A, Eggert A, Reisfeld RA, Lode HN. 2007. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res 67:2331-2338.